MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody
Open accessAbstract
Cancer immunotherapy has been regarded as a promising strategy for cancer therapy by blocking immune checkpoints and evoking immunity to fight cancer, but its efficacy seems to be heterogeneous among patients. Manipulating the gut microbiota is a potential strategy for enhancing the efficacy of immunotherapy. Here, we report that MS-20, also known as “Symbiota®”, a postbiotic that comprises abundant microbial metabolites generated from a soybean-based medium fermented with multiple strains of probiotics and yeast, inhibited colon and lung cancer growth in combination with an anti-programmed cell death 1 (PD1) antibody in xenograft mouse models. Mechanistically, MS-20 remodeled the immunological tumor microenvironment by increasing effector CD8+ T cells and downregulating PD1 expression, which were mediated by the gut microbiota. Fecal microbiota transplantation (FMT) from mice receiving MS-20 treatment to recipient mice increased CD8+ T-cell infiltration into the tumor microenvironment and significantly improved antitumor activity when combined with anti-PD1 therapy. Notably, the abundance of Ruminococcus bromii, which increased following MS-20 treatment, was positively associated with a reduced tumor burden and CD8+ T-cell infiltration in vivo. Furthermore, an ex vivo study revealed that MS-20 could alter the composition of the microbiota in cancer patients, resulting in distinct metabolic pathways associated with favorable responses to immunotherapy. Overall, MS-20 could act as a promising adjuvant agent for enhancing the efficacy of immune checkpoint-mediated antitumor therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MS-20 administered alongside anti-PD-1 therapy in mouse models induced shifts in gut microbial composition, increasing members of the Clostridiaceae and Ruminococcaceae families, while also modulating the immune response and enhancing IgA production.
“When administered alongside anti-PD-1 therapy in mouse models, MS-20 induced shifts in gut microbial composition, increasing members of the Clostridiaceae and Ruminococcaceae families, while also modulating the immune response and enhancing IgA production (Lee et al., 2024).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Lee et al., 2024
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,013 · see citing works
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works
Self-citationCommensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · see citing works
Sparse and Compositionally Robust Inference of Microbial Ecological Networks
Kurtz, Z. D., Müller, C. L., Miraldi, E. R., Littman, D. R., Blaser, M. J., & Bonneau, R. A. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004226 · Cited by 1,799 · see citing works
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781 · cited 1× · see citing works
“…two studies reported that the clinical response rates were 30% (3 of 10) and 20% (3 of 15) in patients with refractory melanoma who were reintroduced to anti-PD1 therapy, 13,14 which were higher than that in patients who were retreated with anti-PD1 therapy alone (5 out of 34, 14.7%).”
BackgroundInfluentialFecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., et al. (2021) · Science · doi:10.1126/science.abb5920 · Cited by 1,757 · see citing works
A defined commensal consortium elicits CD8 T cells and anti-cancer immunity
Tanoue, T., Morita, S., Plichta, D. R., Skelly, A. N., Suda, W., Sugiura, Y., Narushima, S., Vlamakis, H., Motoo, I., Sugita, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0878-z · Cited by 1,145 · see citing works
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069 · see citing works
Ze, X., Duncan, S. H., Louis, P., & Flint, H. J. (2012) · The ISME Journal · doi:10.1038/ismej.2012.4 · Cited by 1,060 · see citing works
Terpou, A., Papadaki, A., Lappa, I., Kachrimanidou, V., Bosnea, L., & Kopsahelis, N. (2019) · Nutrients · doi:10.3390/nu11071591 · Cited by 779 · see citing works
Derosa, L., Routy, B., Thomas, A. M., Iebba, V., Zalcman, G., Friard, S., Mazieres, J., Audigier-Valette, C., Moro-Sibilot, D., Goldwasser, F., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01655-5 · Cited by 685 · see citing works
Zheng, Y., Wang, T., Tu, X., Huang, Y., Zhang, H., Tan, D., Jiang, W., Cai, S., Zhao, P., Song, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0650-9 · Cited by 550 · see citing works
Galdeano, C. M., & Perdigón, G. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.13.2.219-226.2006 · Cited by 535 · see citing works
Sallusto, F., & Lanzavecchia, A. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17717.x · Cited by 526 · see citing works
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526 · see citing works
Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01694-6 · Cited by 515 · see citing works
Targeting the gut and tumor microbiota in cancer
Park, E. M., Chelvanambi, M., Bhutiani, N., Kroemer, G., Zitvogel, L., & Wargo, J. A. (2022) · Nature Medicine · doi:10.1038/s41591-022-01779-2 · Cited by 496 · see citing works
Natural polyreactive IgA antibodies coat the intestinal microbiota
Bunker, J. J., Erickson, S. A., Flynn, T. M., Henry, C., Koval, J., Meisel, M., Jabrì, B., Antonopoulos, D. A., Wilson, P. C., & Bendelac, A. S. (2017) · Science · doi:10.1126/science.aan6619 · Cited by 470 · see citing works
Probiotics, prebiotics, and postbiotics in health and disease
Ji, J., Jin, W., Liu, S., Jiao, Z., & Li, X. (2023) · MedComm · doi:10.1002/mco2.420 · Cited by 416 · see citing works
Liang, Q., Li, T., Nakatsu, G., Chen, Y., Yau, T. O., Chu, E. S., Wong, S. H., Szeto, C. H., Ng, S. C., Chan, F. K. L., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318532 · Cited by 344 · see citing works
Nakajima, A., Vogelzang, A., Maruya, M., Miyajima, M., Murata, M., Son, A., Kuwahara, T., Tsuruyama, T., Yamada, S., Matsuura, M., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180427 · Cited by 340 · see citing works
Comerford, I., Harata‐Lee, Y., Bunting, M. D., Whyte, C. E., Kara, E. E., & McColl, S. R. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.03.001 · Cited by 289 · see citing works
CCL19 and CCL21 Induce a Potent Proinflammatory Differentiation Program in Licensed Dendritic Cells
Marsland, B. J., Bättig, P., Bauer, M., Ruedl, C., Lässing, U., Beerli, R. R., Dietmeier, K., Ivanova, L., Pfister, T., Vogt, L., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.02.010 · Cited by 283 · see citing works
Mao, J., Wang, D., Long, J., Xu, Y., Lin, J., Song, Y., Xie, F., Xun, Z., Wang, Y., Wang, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003334 · Cited by 280 · see citing works
Microbial ecology perturbation in human IgA deficiency
Fadlallah, J., Kafsi, H. E., Sterlin, D., Juste, C., Parizot, C., Dorgham, K., Autaa, G., Gouas, D. A., Almeida, M., Lepage, P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan1217 · Cited by 274 · see citing works
Nagpal, R., Wang, S., Woods, L. C. S., Seshie, O., Chung, S. T., Shively, C. A., Register, T. C., Craft, S., McClain, D. A., & Yadav, H. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02897 · Cited by 270 · see citing works
Microbiome in Colorectal Cancer: How to Get from Meta-omics to Mechanism?
Ternes, D., Karta, J., Tsenkova, M., Wilmes, P., Haan, S., & Letellier, E. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2020.01.001 · Cited by 256 · see citing works
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Giacomo, A. M. D., Mortier, L., Rutkowski, P. L., Hassel, J. C., McNeil, C. M., Kalinka‐Warzocha, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00995 · Cited by 253 · see citing works
Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0808 · Cited by 250 · see citing works
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
Fidelle, M., Rauber, C., Alves Costa Silva, C., Tian, A.-L., Lahmar, I., de La Varende, A.-L. M., Zhao, L., Thelemaque, C., Lebhar, I., Messaoudene, M., et al. (2023) · Science · doi:10.1126/science.abo2296 · Cited by 243 · see citing works
Postbiotics in Human Health: A Narrative Review
Ma, L., Tu, H., & Chen, T. (2023) · Nutrients · doi:10.3390/nu15020291 · Cited by 237 · see citing works
An integrated tumor, immune and microbiome atlas of colon cancer
Roelands, J. P., Kuppen, P. J. K., Ahmed, E. I., Mall, R., Masoodi, T., Singh, P., Monaco, G., Raynaud, C. M., de Miranda, N. F. C. C., Ferraro, L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02324-5 · Cited by 217 · see citing works
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento‐Ribeiro, A. B., García‐Aranda, M., & Rivas, J. D. L. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 200 · see citing works
IgA-deficient humans exhibit gut microbiota dysbiosis despite secretion of compensatory IgM
Catanzaro, J., Strauss, J. D., Bielecka, A., Porto, A. F., Lobo, F. M., Urban, A. D., Schofield, W. B., & Palm, N. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-49923-2 · Cited by 199 · see citing works
Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
Park, J. S., Gazzaniga, F. S., Wu, M., Luthens, A. K., Gillis, J., Zheng, W., LaFleur, M. W., Johnson, S. B., Morad, G., Park, E. M., et al. (2023) · Nature · doi:10.1038/s41586-023-06026-3 · Cited by 191 · see citing works
Hauser, M. A., & Legler, D. F. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.2mr0815-380r · Cited by 190 · see citing works
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Warner, A. B., Palmer, J. S., Shoushtari, A. N., Goldman, D. A., Panageas, K. S., Hayes, S. A., Bajwa, R., Momtaz, P., Callahan, M. K., Wolchok, J. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01464 · Cited by 189 · see citing works
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Zhang, M., Liu, J., & Xia, Q. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00442-x · Cited by 149 · see citing works
Unlocking the power of postbiotics: A revolutionary approach to nutrition for humans and animals
Zhao, X., Liu, S., Li, S., Jiang, W., Wang, J., Xiao, J., Chen, T., Ma, J., Khan, M. Z., Wang, W., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.004 · Cited by 147 · see citing works
Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy
Thomas, A. M., Fidelle, M., Routy, B., Kroemer, G., Wargo, J. A., Segata, N., & Zitvogel, L. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00785-8 · Cited by 141 · see citing works
Capsular polysaccharide correlates with immune response to the human gut microbe Ruminococcus gnavus
Henke, M. T., Brown, E., Cassilly, C. D., Vlamakis, H. C., Xavier, R. J., & Clardy, J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007595118 · Cited by 137 · see citing works
An in vitro model maintaining taxon-specific functional activities of the gut microbiome
Li, L., Abou-Samra, E., Ning, Z., Zhang, X., Mayne, J., Wang, J., Cheng, K., Walker, K., Stintzi, A. P., & Figeys, D. (2019) · Nature Communications · doi:10.1038/s41467-019-12087-8 · Cited by 131 · see citing works
Tostivint, E. P., Latouche, A., Vaflard, P., Ricci, F., Loirat, D., Hescot, S., Sablin, M., Rouzier, R., Kamal, M. T., Morel, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00114 · Cited by 107 · see citing works
Comprehensive mouse microbiota genome catalog reveals major difference to its human counterpart
Kieser, S., Zdobnov, E. M., & Trajkovski, M. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009947 · Cited by 99 · see citing works
The heightened importance of the microbiome in cancer immunotherapy
Villemin, C., Six, A., Neville, B. A., Lawley, T. D., Robinson, M. J., & Bakdash, G. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.11.002 · Cited by 75 · see citing works
Huh, J.-W., Kim, M. J., Kim, J., Lee, H. G., Ryoo, S. B., Ku, J.-L., Jeong, S.-Y., Park, K. J., Kim, J. F., Kim, J. F., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01388-8 · Cited by 74 · see citing works
Dóra, D., Ligeti, B., Kovács, T., Revisnyei, P., Gálffy, G., Dulka, E., Krizsán, D., Kalcsevszki, R., Megyesfalvi, Z., Döme, B., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2204746 · Cited by 63 · see citing works
Gut Microbiota Perturbation in IgA Deficiency Is Influenced by IgA-Autoantibody Status
Moll, J. M., Myers, P. N., Zhang, C., Eriksen, C., Wolf, J., Appelberg, K. S., Lindberg, G., Bahl, M. I., Zhao, H., Pan‐Hammarström, Q., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.053 · Cited by 57 · see citing works
Joglekar, P., Ding, H., Canales-Herrerías, P., Pasricha, P. J., Sonnenburg, J. L., & Peterson, D. A. (2019) · mBio · doi:10.1128/mbio.02324-19 · Cited by 51 · see citing works
Growth Inhibition and Induction of Apoptosis in MCF-7 Breast Cancer Cells by Fermented Soy Milk
Chang, W.-H., Liu, J., Chen, C., Huang, T., & Lu, F.-J. (2002) · Nutrition and Cancer · doi:10.1207/s15327914nc432_12 · Cited by 45 · see citing works
Gut microbial structural variation associates with immune checkpoint inhibitor response
Liu, R., Zou, Y., Wang, W.-Q., Chen, J.-H., Zhang, L., Feng, J., Yin, J.-Y., Mao, X.-Y., Li, Q., Luo, Z.-Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42997-7 · Cited by 45 · see citing works
Modulating gut microbiota to treat cancer
Woelk, C. H., & Snyder, A. (2021) · Science · doi:10.1126/science.abg2904 · Cited by 42 · see citing works
Role of Defensins in Tumor Biology
Adyns, L., Proost, P., & Struyf, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065268 · Cited by 42 · see citing works
Tang, Y., Feng, X., Lü, Q., Cui, C., Yu, M., Wen, Z., Luan, Y., Dong, L., Hu, Z., Zhang, R., et al. (2023) · Mucosal Immunology · doi:10.1016/j.mucimm.2023.12.002 · Cited by 26 · see citing works
Chemokines and receptors in intestinal B lymphocytes
Zhiming, W., Wang, L., Tingting, Q., & Yiwei, C. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ru0717-299rr · Cited by 20 · see citing works
Tsang, Y., Chi, K., Hu, C.-J., Tseng, C.-L., Tseng, F.-W., & Wang, Y. (2007) · Nutrition Research · doi:10.1016/j.nutres.2007.09.001 · Cited by 18 · see citing works
Immune modulation effects of soya bean fermentation food evaluated by an animal model
Chin, Y.-P., Hung, C.-Y., Yang, C. Y., Wang, C. Y., & Lin, Y. L. (2014) · Food and Agricultural Immunology · doi:10.1080/09540105.2014.968766 · Cited by 11 · see citing works
Self-citationDai, K., Huang, L., Huang, Y., Chen, Z., Yang, L.-H., & Jiang, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00320 · Cited by 11 · see citing works
Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
Li, B., Gong, T., Hao, Y., Zhou, X., & Cheng, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.721249 · Cited by 9 · see citing works
Hung, C., Chu, W., Huang, W., Lee, P., Kuo, W., Hou, C.-Y., Yang, C., Yang, A., Wu, W., Kuo, M.-L., et al. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.3921 · Cited by 5 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [10]Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Sci (New Y, NY). 2018; 359(6371): 97– 103. doi: 10.1126/science.aan4236. PMC5827966 29097493 · DOI · Paper page
Cited by
Sorted by citations
Respiratory diseases and the gut microbiota: an updated review
Xin, Y., Yu, X., Wang, Y., Guo, X., Wang, C., & Wang, F. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1629005 · Cited by 38 · see citing works
Lu, Y., Yuan, H., Liang, S., Li, D., Jiang, P., Wang, X., Zhang, K., & Liu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603658 · Cited by 38 · see citing works
Chen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 22 · see citing works
D’Amore, T., Zolfanelli, C., Lauciello, V., Ciancia, A. D., Vagliasindi, A., Smaoui, S., & Varzakas, T. H. (2025) · Microorganisms · doi:10.3390/microorganisms13061335 · Cited by 20 · see citing works
Microbiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19 · see citing works
Zhang, W., Zhang, H., Gao, Y., Lei, J., & Suo, C. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1596688 · Cited by 12 · see citing works
Microbial metabolites for cancer immunotherapy: Current evidence and future directions
Wang, X., Liang, J.-J., Duan, X., & Chen, G. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.005 · Cited by 10 · see citing works
Circadian rhythms as a modulator of gut microbiota-tumor microenvironment crosstalk
Xu, Q., Lin, A., Jiang, A., Chen, L., Zhu, L., Mou, W., Liu, Z., Zhang, J., Cheng, Q., Miao, K., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05935-y · Cited by 9 · see citing works
Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy
Hu, J., Feng, T., Zhang, L., Zhou, Q., & Zhu, L. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003687 · Cited by 7 · see citing works
The gut microbiome in lung cancer: from pathogenesis to precision therapy
Shi, M. K., Wang, L., Hu, W., & Liang, Z. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1606684 · Cited by 7 · see citing works
Chen, Y., & Tang, D. (2025) · Future Oncology · doi:10.1080/14796694.2025.2558287 · Cited by 6 · see citing works
Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy
Lu, Q., Wu, J., Yu, X., Qian, J., & Song, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690374 · Cited by 6 · see citing works
Wu, Q., Zhou, Y.-R., Chen, Z.-R., Liu, M.-X., Liu, M.-X., Liu, Y.-F., Li, Z., Zhao, Q.-R., Zhang, Y.-Q., Zhang, H., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105230 · Cited by 4 · see citing works
Leghari, A., Khand, F. M., Laghari, S., & Lakho, S. A. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.151123 · Cited by 4 · see citing works
Lin, Z., Mu, S., Zhang, W., Guo, Y., Dong, C., Song, L., Zhang, H., Wu, R., Luo, P., & Liang, L. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102428 · Cited by 4 · see citing works
Jiang, X., Xu, Y., Shen, B., Ji, Y., Shi, L., Gao, J., & Dong, J. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01256 · Cited by 2 · see citing works
Xu, H., Geng, W., He, J., Jia, L., Zhao, G., & Wang, Y. (2026) · Food Research International · doi:10.1016/j.foodres.2026.118921 · Cited by 2 · see citing works
Yao, T., Xiong, Y., Hu, Q., Chen, Y., Li, D., Yan, J., Yang, J., Wang, Y., Cao, H., Zhang, F., et al. (2026) · BMC Microbiology · doi:10.1186/s12866-025-04591-3 · Cited by 1 · see citing works
Yu, S., Shu, W., Zhang, J., Cheng, S., Shen, X., Chen, G., Zhang, T., Dong, K., Zhang, J., Laudański, P., et al. (2026) · International Journal of Women s Health · doi:10.2147/ijwh.s583327 · Cited by 1 · see citing works
Bi, Q., Zhang, L., Wan, H., & Zhang, J. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11988-4 · Cited by 1 · see citing works
The impact of gut microbiota and metabolite-driven immune cell spatiotemporal dynamics on tumors
Ding, J., Lin, M., Zang, D., & Chen, J. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2681842 · Cited by 1 · see citing works
Wang, Y., Tian, Z.-M., Zhou, Z.-J., Chen, L., Zhu, X., Yu, K., & Qiu, Y. (2024) · journal of nutritional oncology · doi:10.1097/jn9.0000000000000043
Zhuang, A., Xi, Z., Cheng, Y., Zhang, C.-H., & Li, W. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i2.81
Xu, Y., Wen, B., & Li, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1629495
Host and gut microbiota crosstalk: A new paradigm for colorectal cancer immunotherapy
Ti, D.-D., Liu, P., Wu, C.-Y., Shi, Z., Guo, S.-M., & Gao, Z. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i4.118606
Le, Q.-R., Li, G.-Z., Luo, Y., Chen, H.-X., Chen, W.-T., Liu, N.-N., & Xiao, J. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108293
Self-citation朱利明, Xu, J. Q., Niu, D., Zhang, X., & Jin, C. (2026) · Cancer Medicine · doi:10.1002/cam4.72061
Abebaw, D., Adugna, A., Tegegne, B. A., Teffera, Z. H., Selabat, B., Kindie, Y., Tilahun, M., Belew, H., Baylie, T., Mengistu, G., et al. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02222-3
Zhang, Y., Wang, S., Chang, S., Li, Y., Dang, Y., & Wang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1803970
Advances in Immunological Combination Therapy for Colorectal Cancer
Wu, J., Wen, R., Zhang, T., Cao, F., Zhu, X., Hao, L., Zhang, W., & Yu, G. (2026) · iMetaMed · doi:10.1002/imm3.70053
The role of pharmacomicrobiomics in colorectal cancer therapy
Feng, X., Pora, M., Ebert, M., Zimmermann, M., & Zhan, T. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.07.006
Ye, S., Tian, T., Huangfu, J., Liu, H., Liu, P., & Zhou, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1999117
- Authors
- Lee, P.-J., Hung, C.-M., Yang, A.-J., Hou, C.-Y., Chou, H.-W., Chang, Y.-C., Chu, W.-C., Huang, W.-Y., Kuo, W.-C., Yang, C.-C., Lin, K.-I., Hung, K.-H., Chang, L.-C., Lee, K.-Y., Kuo, H.-P., Lu, K.-M., Lai, H.-C., Kuo, M.-L., & Chen, W.-J.
- Affiliations
- Pharmaceutical Research & Development, Microbio Co, Ltd, Taipei, Taiwan
- Oneness Biotech Co., Ltd. (Taiwan) (TW)
- Nucleic Acid Drug Division, Microbio (Shanghai) Biotech Company, Shanghai, China
- Genomics Research Center, Academia Sinica (TW)
- National Taiwan University Hospital (TW)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Taipei Medical University Hospital (TW)
- General manager’s office, Microbio Co., Ltd., Taipei, Taiwan
- General manager’s office, Revivebio Co, Ltd, Taipei, Taiwan
- ORCID
- Venue
- Gut Microbes
- Publisher
- Informa UK Limited
- Published
- 2024-07-30
- Volume
- 16
- Issue
- 1
- Pages
- 2380061-2380061
- ISSN
- 1949-0976 (ISSN-L)
- 1949-0984
- PMC
- PMC11290773
- OpenAlex
- W4401127066
- Cited by
- 33
- References
- 61
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 1
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Gut Microbes (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Microbio Co., Ltd
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- Symbiota, postbiotics, gut microbiota, anti-PD-1, cancer immunotherapy, immune checkpoint blockade, tumor microenvironment, CD8+ T cells, Ruminococcus bromii, fecal microbiota transplantation, colon cancer, lung cancer, immunotherapy response
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors, Animals, Colonic Neoplasms, Female, Humans, Immunotherapy, Lung Neoplasms, Mice, Inbred BALB C, CD8-Positive T-Lymphocytes, Probiotics, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
